Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
Versant unveils Pep2Tango, a biotech with next-gen obesity hopes
Versant has unveiled Pep2Tango, a biotech developing next-gen obesity therapeutics with multiple targets to overcome GLP-1 limitations.
Gabrielle Masson
Nov 21, 2024 11:11am
Metsera follows phase 1 weight loss data with $215M series B
Nov 13, 2024 9:15am
AstraZeneca still 'playing to win' in obesity, execs say
Nov 4, 2024 11:49am
In $285M deal, Novo taps Ascendis to help create monthly GLP-1
Nov 4, 2024 8:43am
Viking oral obesity med posts 6.8% weight loss for highest dose
Nov 4, 2024 7:30am
Chinese insulin maker’s GLP-1 bests Ozempic in ph. 2, company says
Oct 15, 2024 11:12am
